Re: Scripts week ending 2/17
I think the hesitancy in share price is related to the uncertain outcome with REDUCE-IT trial. If that thing comes back ambiguous or god forbid, negative, it throws into question this whole sector of drugs. It's that which is keeping me on the sidelines for now. I'm only speaking for myself, but I'm guessing there are many others out there that don't want the risk associated with that. I've been burned a lot on these binary events so I'll sit it out until the results are known.
If the results of REDUCE-IT are good, then I think share price doubles immediately and progressively increases as sales take off.